NEW YORK, Oct. 13, 2016 /PRNewswire/ -- Phosphorus, a computational genomics company, will present findings from its large-scale FertilityMap research study at the American Society for Reproductive Medicine (ASRM) Scientific Congress in Salt Lake City next week. FertilityMap is a first-of-its-kind, IRB-approved study utilizing genomics and big data to bring clarity to the infertility journey. The goal of the study is to develop predictive algorithms to inform infertility diagnosis, prognosis, and treatment in both males and females to ultimately improve pregnancy success rates. To learn more about the FertilityMap study, visit http://phosphorus.com/research.
While a wealth of research has demonstrated that genetics play a critical role in infertility diagnosis and treatment outcomes, the translation of these findings from the bench to bedside has lagged. Phosphorus scientists will present three abstracts at this year's event. The abstracts highlight efforts to unravel the complex nature of infertility using large populations and datasets and to develop new advanced methodologies for infertility diagnosis:
- "FSHR Ser680Asn: Correlation with FSH Levels." Presents preliminary analysis of fertility potential in women using genetic data, and validates results previously shown in the literature. (O-200. Sara Bristow, Ph.D., Wednesday, October 19 at 11:30am).
- "What Influences Anti-Müllerian Hormone Levels?" A complex analytical strategy reveals combinations of single nucleotide polymorphisms in key hormone signaling genes, which affect serum hormone levels. (P-594 Sara Bristow, Ph.D, Tuesday, October 18 at 7:00am).
- "Detecting Y-Chromosome Microdeletions using Next Generation Sequencing (NGS) Data." Discusses a new methodology to detect Y-chromosome microdeletions, a common cause of oligospermia and azoospermia. Utilizing next-generation sequencing and computational algorithms, it is possible to detect Y-chromosome microdeletions at high resolution. (P-321. Roman Shraga, Tuesday, October 18 at 7:00am).
Phosphorus is partnered with Recombine, a CooperSurgical company and a leading provider in genetic testing for reproductive health, to conduct the FertilityMap study. Together with more than 20 top IVF clinics across the country, the partners have enrolled thousands of patients to date. The power of the FertilityMap study comes from its uniquely comprehensive scope, analyzing hundreds of clinical variables and thousands of genetic variants in the context of each participant's personal and family medical history.
Phosphorus is a computational genomics company with the vision to create a world where every healthcare decision is optimized with genomics. Founded in 2016 and based in New York City, Phosphorus develops powerful data-driven software that enables labs around the world to deliver the most advanced clinical genetic tests. Phosphorus is committed to an active research and development program with an initial focus on decoding the genetic causes of infertility. With a team of experts in computational biology and computer science, Phosphorus is building a data network that will help providers, researchers and patients around the world better understand and harness the power of the human genome. For more information visit: www.phosphorus.com and @phosphorus.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/phosphorus-scientists-to-present-early-findings-from-large-scale-fertilitymap-study-at-the-asrm-scientific-congress-300344423.html